Screener
Gyre Therapeutics, Inc. GYRE Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
FAQ
- What is Gyre Therapeutics, Inc.'s total liabilities?
- Gyre Therapeutics, Inc. (GYRE) reported total liabilities of $34.34M in Q2 2026.
- How has Gyre Therapeutics, Inc.'s total liabilities changed year-over-year?
- Gyre Therapeutics, Inc.'s total liabilities increased by 48.0% year-over-year, from $23.2M to $34.34M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Gyre Therapeutics, Inc.'s total liabilities has grown at a 10.8% compound annual growth rate (CAGR), from $18.78M to $31.4M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Gyre Therapeutics, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude